A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms iCare4
- 27 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 04 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
- 25 Jan 2018 Planned End Date changed from 1 Jul 2021 to 1 Nov 2021.